We report a rare case of severe myopericarditis in a healthy man in his 20s after the third dose of an mRNA COVID-19 vaccine. His symptoms and troponinemia resolved with a beta-blocker in addition to standard anti-inflammatory therapy, highlighting the utility of multimodal therapy.
- Cardiovascular medicine
- Pericardial disease
- Immunological products and vaccines
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors ROF was the lead author for this manuscript. She was the senior medical student caring for the patient, and she led the writing and revising of the manuscript. OB was the senior resident during the case. He was actively involved in the patient’s care, and he contributed to conceptualising, drafting and revising the manuscript. TC was a resident who contributed to patient care, drafting the manuscript (specifically parts of the Discussion section) and creating the cMR figure. JK was a resident who was actively involved in caring for the patient, revising the manuscript, creating the troponin versus time graft and adjusting the image quality of all figures. Mohammad Al-Ani was an attending physician who read the patient’s cMR and identified key images to use for our figures. He also helped conceptualise and revise the manuscript. Abdullah Omar was the attending physician during the case. He was directly involved in the patient’s care as well as conceptualising, writing and revising the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.